A CRISPR Activation Screen Identifies a Pan-avian Influenza Virus Inhibitory Host Factor
Author(s) -
Brook E. Heaton,
Edward M. Kennedy,
Rebekah E. Dumm,
Alfred T. Harding,
Matthew T. Sacco,
David Sachs,
Nicholas S. Heaton
Publication year - 2017
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2017.07.060
Subject(s) - crispr , biology , virus , virology , influenza a virus , influenza a virus subtype h5n1 , sialic acid , host (biology) , pathogen , genome , h5n1 genetic structure , disease , gene , microbiology and biotechnology , genetics , infectious disease (medical specialty) , covid-19 , medicine , pathology
Influenza A virus (IAV) is a pathogen that poses significant risks to human health. It is therefore critical to develop strategies to prevent influenza disease. Many loss-of-function screens have been performed to identify the host proteins required for viral infection. However, there has been no systematic screen to identify the host factors that, when overexpressed, are sufficient to prevent infection. In this study, we used CRISPR/dCas9 activation technology to perform a genome-wide overexpression screen to identify IAV restriction factors. The major hit from our screen, B4GALNT2, showed inhibitory activity against influenza viruses with an α2,3-linked sialic acid receptor preference. B4GALNT2 overexpression prevented the infection of every avian influenza virus strain tested, including the H5, H9, and H7 subtypes, which have previously caused disease in humans. Thus, we have used CRISPR/dCas9 activation technology to identify a factor that can abolish infection by avian influenza viruses.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom